BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide
March 26, 2018 at 08:19 AM EDT
* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:
